Dr. Schapiro is developing methods to uncover patient-specific biomarkers that can guide therapeutic decisions for melanoma. He will collect data using miniaturized devices that enable complex measurements of tumors before and after they are exposed to drugs. Using new computational algorithms, he hopes to discover the cellular and molecular features associated with drug responsiveness and resistance to guide treatment options in patients.